Published in Endoscopy on July 28, 2010
Management of early gastrointestinal neuroendocrine neoplasms. World J Gastrointest Endosc (2011) 1.15
Current concepts on gastric carcinoid tumors. Gastroenterol Res Pract (2012) 1.04
Histopathology of gastrointestinal neuroendocrine neoplasms. Front Oncol (2013) 1.04
Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study. World J Gastroenterol (2012) 1.00
Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. Diagnostics (Basel) (2015) 0.98
Long-term follow up of endoscopic resection for type 3 gastric NET. World J Gastroenterol (2013) 0.94
Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J Gastroenterol (2013) 0.92
Management of early asymptomatic gastrointestinal stromal tumors of the stomach. World J Gastrointest Endosc (2014) 0.90
Neuroendocrine liver metastases: contributions of endoscopy and surgery to primary tumor search. World J Gastroenterol (2012) 0.87
Clinical impact of endoscopic submucosal dissection for gastric neuroendocrine tumors: a retrospective study from mainland China. ScientificWorldJournal (2012) 0.86
Endoscopic treatment for early foregut neuroendocrine tumors. Clin Endosc (2013) 0.81
Endoscopic diagnosis and management of type I neuroendocrine tumors. World J Gastrointest Endosc (2015) 0.79
Gastroenteropancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1. Cancers (Basel) (2012) 0.79
Multiple Endocrine Neoplasia: Genetics and Clinical Management. Surg Oncol Clin N Am (2015) 0.77
A case of mixed adenoneuroendocrine carcinoma of the stomach with focal intestinal metaplasia and hypergastrinemia. Int Surg (2015) 0.75
Management of gastric and duodenal neuroendocrine tumors. World J Gastroenterol (2016) 0.75
Late anastomotic perforation following surgery for gastric neuroendocrine tumor complicated by perforated duodenal ulcer: a case report. J Biomed Res (2012) 0.75
Recurrent gastric neuroendocrine tumors treated with total gastrectomy. World J Gastroenterol (2015) 0.75
Advances in the diagnosis and treatment of gastric neuroendocrine neoplasms. Transl Gastroenterol Hepatol (2016) 0.75
Early diagnosis and treatment of gastrointestinal neuroendocrine tumors. Oncol Lett (2016) 0.75
Gastric and rectal carcinoids. Endoscopy (2010) 0.75
Pathophysiology of Gastric NETs: Role of Gastrin and Menin. Curr Gastroenterol Rep (2017) 0.75
Different long-term oncologic outcomes after radical surgical resection for neuroendocrine carcinoma and adenocarcinoma of the stomach. Oncotarget (2017) 0.75
Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol (2001) 6.30
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch (2006) 5.86
Transluminal endoscopic necrosectomy after acute pancreatitis: a multicentre study with long-term follow-up (the GEPARD Study). Gut (2009) 5.08
Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res (1985) 4.39
TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch (2007) 3.89
Course of alcoholic chronic pancreatitis: a prospective clinicomorphological long-term study. Gastroenterology (1996) 3.81
Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol (1999) 3.36
Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med (1999) 3.21
Non-alcoholic duct destructive chronic pancreatitis. Gut (1997) 2.79
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch (2001) 2.73
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer (1991) 2.52
Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med (1996) 2.51
Biopsy surveillance is still necessary in patients with Barrett's oesophagus despite new endoscopic imaging techniques. Gut (2003) 2.49
The Munich Polypectomy Study (MUPS): prospective analysis of complications and risk factors in 4000 colonic snare polypectomies. Endoscopy (2005) 2.49
Cystic neoplasms of the pancreas and tumor-like lesions with cystic features: a review of 418 cases and a classification proposal. Virchows Arch (2004) 2.44
Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther (2014) 2.42
Miniprobe confocal laser microscopy for the detection of invisible neoplasia in patients with Barrett's oesophagus. Gut (2008) 2.20
Duct- to islet-cell differentiation and islet growth in the pancreas of duct-ligated adult rats. Diabetologia (1995) 2.19
Endosonographic differentiation of benign and malignant stromal cell tumors. Gastrointest Endosc (1997) 2.16
Intraductal mucin-hypersecreting neoplasms of the pancreas. A clinicopathologic study of eight patients. Gastroenterology (1991) 2.14
Probe-based confocal laser endomicroscopy compared with standard four-quadrant biopsy for evaluation of neoplasia in Barrett's esophagus. Endoscopy (2010) 2.11
Diamond stents for palliation of malignant bile duct obstruction: a prospective multicenter evaluation. Endoscopy (2001) 2.07
Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut (2005) 2.07
Solid-pseudopapillary tumor of the pancreas: its origin revisited. Virchows Arch (2000) 1.98
Assessment and prediction of long-term cure in patients with the Zollinger-Ellison syndrome: the best approach. Ann Intern Med (1993) 1.94
Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med (1999) 1.92
Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch (1995) 1.91
Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) (2000) 1.88
Residual insulin positivity and pancreatic atrophy in relation to duration of chronic type 1 (insulin-dependent) diabetes mellitus and microangiopathy. Diabetologia (1987) 1.85
Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study. Ann Intern Med (1989) 1.78
Localization and surgical treatment of occult insulinomas. Ann Surg (1990) 1.76
WNT5A--target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis (2007) 1.76
Intraductal papillary mucinous tumours of the pancreas. Clinical and therapeutic issues in 32 patients. Gut (1996) 1.74
Surgery for ductal adenocarcinoma of the pancreatic head: staging, complications, and survival after regional versus extended lymphadenectomy. World J Surg (2000) 1.72
Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study. Ann Surg (1992) 1.71
Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol (2001) 1.69
Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology (1990) 1.68
False-positive somatostatin receptor scintigraphy due to an accessory spleen. J Nucl Med (1997) 1.67
Key importance of the Helicobacter pylori adherence factor blood group antigen binding adhesin during chronic gastric inflammation. Cancer Res (2001) 1.67
Endoscopic submucosal dissection (ESD) of early neoplastic gastric lesions using a new double-channel endoscope (the "R-scope"). Endoscopy (2006) 1.65
Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci U S A (2000) 1.64
Malignant transformation of duct-like cells originating from acini in transforming growth factor transgenic mice. Gastroenterology (1998) 1.60
Inflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotion. Proc Natl Acad Sci U S A (2009) 1.60
Multicentre prospective controlled study of Barrett's oesophagus and colorectal adenomas. Groupe d'Etude de l'Oesophage de Barrett. Lancet (1995) 1.59
Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol (1999) 1.59
Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. Dig Dis Sci (1989) 1.57
Gastrinomas: localization by means of selective intraarterial injection of secretin. Radiology (1990) 1.56
Pancreatic endocrine tumors. Hum Pathol (1982) 1.55
Glucose promotes survival of rat pancreatic beta cells by activating synthesis of proteins which suppress a constitutive apoptotic program. J Clin Invest (1996) 1.55
Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch (1994) 1.54
Exocrine pancreatic tumours and their histological classification. A study based on 167 autopsy and 97 surgical cases. Histopathology (1983) 1.54
Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer (1999) 1.52
Loss of membranous E-cadherin expression in pancreatic cancer: correlation with lymph node metastasis, high grade, and advanced stage. J Pathol (1994) 1.51
Characteristics of cell lines established from human gastric carcinoma. Cancer Res (1990) 1.49
Use of omeprazole in patients with Zollinger-Ellison syndrome. Dig Dis Sci (1991) 1.49
The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma. Am J Surg Pathol (2001) 1.48
Intraductal papillary neoplasms of the pancreas. A clinicopathologic study of six patients. Cancer (1989) 1.48
[S3-guidelines--sedation in gastrointestinal endoscopy]. Z Gastroenterol (2008) 1.47
The epidermal growth factor receptor in human pancreatic cancer. J Pathol (1992) 1.47
Idiosyncratic drug allergic phenprocoumon-induced hepatitis with subacute liver failure initially misdiagnosed as autoimmune hepatitis. Scand J Gastroenterol (2001) 1.47
Staging and outcome depending on surgical treatment in adenocarcinomas of the oesophagogastric junction. Br J Surg (2012) 1.46
Expression of the tumor suppressor gene Maspin in human pancreatic cancers. Clin Cancer Res (2001) 1.46
Ischaemic colitis in a patient taking meloxicam. Lancet (2001) 1.45
Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome. Ann Surg (1986) 1.44
DNA ploidy and cell-cycle analysis in pancreatic and ampullary carcinoma: flow cytometric study of formalin-fixed paraffin-embedded tissue. Virchows Arch A Pathol Anat Histopathol (1990) 1.43
Interaction of cholecystokinin with specific membrane receptors on pancreatic acinar cells. Proc Natl Acad Sci U S A (1980) 1.43
Zollinger-Ellison syndrome: current concepts and management. Ann Intern Med (1983) 1.42
Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg (1998) 1.42
Performance, patient acceptance, appropriateness of indications and potential influence on outcome of EUS: a prospective study in 397 consecutive patients. Gastrointest Endosc (1999) 1.40
Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors. Cancer Res (1998) 1.40
Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation. Am J Pathol (1993) 1.39
Pseudotuberculous pyelonephritis associated with nephrolithiasis. Am J Surg Pathol (1992) 1.38
Interactions of COOH-terminal fragments of cholecystokinin with receptors on dispersed acini from guinea pig pancreas. J Biol Chem (1982) 1.37
Pancreatic intraepithelial neoplasia revisited and updated. Pancreatology (2008) 1.35
Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors. J Biol Chem (1997) 1.33
Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology (1992) 1.33
Differential diagnosis of gastrointestinal carcinomas by using monoclonal antibodies specific for individual keratin polypeptides. Lab Invest (1986) 1.32
Interaction of bombesin and litorin with specific membrane receptors on pancreatic acinar cells. Proc Natl Acad Sci U S A (1978) 1.30
The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. Cancer (1999) 1.29
Immunocytochemistry of paragangliomas--value of staining for S-100 protein and glial fibrillary acid protein in diagnosis and prognosis. Histopathology (1991) 1.28
Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology (2004) 1.28
The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay. Brain Res (1981) 1.27
Intraoperative ultrasonographic localization of islet cell tumors. A prospective comparison to palpation. Ann Surg (1988) 1.27
Immunocytochemical markers of uncommon pancreatic tumors. Acinar cell carcinoma, pancreatoblastoma, and solid cystic (papillary-cystic) tumor. Cancer (1987) 1.27
Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene (2006) 1.27
The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol (2000) 1.26
Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. Proc Natl Acad Sci U S A (1992) 1.26
A synthetic peptide that is a bombesin receptor antagonist. Nature (1984) 1.24
Diffuse and focal nesidioblastosis. A clinicopathological study of 24 patients with persistent neonatal hyperinsulinemic hypoglycemia. Am J Surg Pathol (1989) 1.24
Evaluation of endocytoscopy in the surveillance of patients with Barrett's esophagus. Endoscopy (2007) 1.24
Undifferentiated carcinoma of the pancreas: analysis of intermediate filament profile and Ki-ras mutations provides evidence of a ductal origin. J Pathol (1998) 1.24
Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. N Engl J Med (1985) 1.24
Human colon cancer cell proliferation mediated by the M3 muscarinic cholinergic receptor. Clin Cancer Res (1999) 1.23
Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology (1997) 1.23
Duct changes and K-ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution. Virchows Arch (1999) 1.22